Drug Trial Radar · NCT07785063
Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
May 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- Longbio Pharma (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of LP-003 for an increasing the amount of peanut protein that people with a peanut allergy can tolerate without having allergic symptoms. The study will include participants 12 to 55 years of age with a confirmed peanut allergy. Participants will be randomly assigned to receive LP-003 or placebo. LP-003 will be given by an injection under the skin (subcutaneous) once every 8 weeks during the first 24 weeks of treatment. Participants will not know the treatment they are receiving until the end of the study. The primary efficacy endpoints will be the proportion of participants in each group who successfully consume a single dose of ≥600 mg of peanut protein during a supervised double-blind, placebo-controlled food challenge at Week 24. Participants who complete the 24 weeks will continue for another 24 weeks in a blinded (participants will not know what treatment they are on) extension period, followed by a blinded follow-up period for continued safety, pharmacokinetic, pharmacodynamic, and immunogenicity assessments. The total study duration for each participant is approximately 84 weeks.
Conditions
- Peanut Allergies
Interventions
LP-003 InjectionDrug
The active ingredient of LP-003 Injection is a humanized anti-IgE monoclonal antibody. There are two dose groups, 300mg and 600mg: each administered as a subcutaneous injection site, Q8W.
Placebo InjectionDrug
Placebo is a sterile injectable solution matched to LP-003 for appearance, formulation, and administration, with 0 mg of active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Without Dose Limiting SymptomsTime frame: From initial administration of the investigational product (Day1) up to and including Week 24 (Day 141).
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Cenexel Marlton
Marlton, New Jersey
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Murdoch Children's Research Institute
Parkville, Victoria, Australia
Perth Children's Hospital
Nedlands, Western Australia, Australia
Fiona Stanley Hospital
Perth, Western Australia, Australia
Halton Pediatric Allergy
Burlington, Ontario, Canada
Triple A Labs
Hamilton, Ontario, Canada
University of McMaster
Hamilton, Ontario, Canada
Allergy Research Canada
Niagara Falls, Ontario, Canada
University of Montreal
Montreal, Quebec, Canada
The Capital Region Allergy Clinic
Québec, Quebec, Canada
The Chinese University of Hong Kong Clinical Trial Centre
Hong Kong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.